市场监管总局严打药品垄断，三年罚没超24亿元

Core Viewpoint - The article highlights the increasing prevalence of drug monopoly behaviors in certain sectors, which have led to rising drug prices and disrupted markets, thereby increasing the burden on the public for medication costs [1][2]. Group 1: Regulatory Actions - The State Administration for Market Regulation (SAMR) has investigated and penalized 12 cases of drug monopoly agreements and abuse of market dominance over the past three years, with total fines exceeding 2.4 billion RMB [1]. - In a specific case involving Shanghai Xinyi United Pharmaceutical Co., over 850 enforcement personnel were mobilized across 10 provinces to investigate more than 40 upstream and downstream companies, leading to rapid identification and resolution of monopolistic behaviors [1]. Group 2: Penalties and Guidelines - All 12 drug monopoly cases were subjected to severe penalties, with an average fine amounting to 5% of the involved companies' sales from the previous year, and an average single case fine exceeding 200 million RMB [2]. - The SAMR has introduced a new guideline on drug-related antitrust actions, clarifying the identification rules for typical monopolistic behaviors such as joint price increases and abuse of market dominance, thereby providing clear compliance guidance for pharmaceutical companies [2]. Group 3: Collaborative Efforts - The SAMR has strengthened collaboration with health, police, medical insurance, and drug supervision departments to form a united front in discovering leads, investigating, sharing information, and implementing joint penalties [3]. - The enforcement actions have resulted in significant reductions in the prices of related drugs, demonstrating the effectiveness of the regulatory measures [3].